Targeting death receptors: is this trail still hot?

Despite tremendous improvements in the survival of patients with pediatric solid tumors, outcomes for metastatic solid tumors and tumors that fail upfront therapy remains dismal (1,2). Further dose intensification of cytotoxic chemotherapy and radiation has not improved survival and new treatment strategies are desperately needed.